股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 第 1 頁 共 10 頁 v 1.2.1 截至月份: 2026年3月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 永勝醫療控股有限公司 呈交日期: 2026年4月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01612 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | HKD | | 0.01 HKD | | 100,000,000 | | 增加 / 減少 (-) | | | 0 | | | HKD | | 0 | | 本月底結存 | | | 10,000,000,000 | HKD | | 0.01 HKD | | 100,000,000 | ...

EF001 免責聲明 | 公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 | 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因 | | --- | --- | | 股票發行人現金股息公告 | | | 發行人名稱 | 永勝醫療控股有限公司 | | 股份代號 | 01612 | | 多櫃檯股份代號及貨幣 | 不適用 | | 相關股份代號及名稱 | 不適用 | | 公告標題 | 截至2025年12月31日止年度之末期股息 | | 公告日期 | 2026年3月25日 | | 公告狀態 | 新公告 | | 股息信息 | | | 股息類型 | 末期 | | 股息性質 | 普通股息 | | 財政年末 | 2025年12月31日 | | 宣派股息的報告期末 | 2025年12月31日 | | 宣派股息 | 每 股 0.026 HKD | | 股東批准日期 | 2026年5月20日 | | 香港過戶登記處相關信息 | | | 派息金額及公司預設派發貨幣 | 每 股 0.026 HKD | | 匯率 | 1 HKD : 1 ...

Revenue and Profit Performance - Revenue for the year ended December 31, 2025, increased by 16.5% to HKD 932.8 million, compared to HKD 801.0 million in 2024[3] - Profit for the year increased by 52.8% to HKD 108.4 million, with a net profit margin rising to 11.6% from 8.9% in 2024[3] - Total revenue for 2025 reached HKD 932,784,000, an increase of 16.4% from HKD 800,963,000 in 2024[30] - The total profit for 2025 was HKD 163,014,000, compared to HKD 100,401,000 in 2024, representing a 62.2% increase[30] - The company's profit attributable to owners increased to HKD 104,378,000 in 2025, up from HKD 69,167,000 in 2024, indicating a growth of around 51%[38] Revenue Breakdown by Segment - Revenue from the imaging disposable products segment rose by 39.8% to HKD 549.7 million, accounting for 58.9% of total revenue, up from 49.1% in 2024[3] - Revenue from the respiratory products segment remained stable at HKD 243.2 million, representing about 26.1% of total revenue, with a gross profit margin of 39.3%[48] - Revenue from the healthcare and wellness products segment decreased by 4.3% to HKD 107.1 million, accounting for 11.5% of total revenue[49] - The orthopedic rehabilitation devices segment saw a decline in revenue from HKD 50.2 million to HKD 32.8 million, representing approximately 3.5% of total revenue[50] Dividend and Shareholder Information - The board proposed a final dividend of HKD 0.026 per share, totaling HKD 0.050 per share for the year, compared to HKD 0.033 per share in 2024[3] - The company declared a final dividend of HKD 0.026 per share for the year ending December 31, 2025, subject to shareholder approval[37] - The proposed final dividend is HKD 0.026 per share, up from HKD 0.017 per share in 2024, bringing the total dividend for the year to HKD 0.050 per share[79] - The company will hold its annual general meeting on May 20, 2026, with a record date for the proposed final dividend on June 1, 2026[82] Assets and Liabilities - Total assets increased to HKD 1,171.5 million in 2025 from HKD 919.7 million in 2024[6] - Non-current assets rose to HKD 472.7 million in 2025, up from HKD 332.0 million in 2024[6] - Current assets totaled HKD 698.8 million, compared to HKD 587.7 million in 2024[6] - Total equity increased to HKD 673.2 million in 2025 from HKD 583.4 million in 2024[6] - Trade receivables rose to HKD 197,708,000 in 2025 from HKD 173,086,000 in 2024, an increase of approximately 14%[40] - Accounts receivable increased to HKD 194,758,000 in 2025 from HKD 169,332,000 in 2024, reflecting a growth of 15.1%[24] - Total borrowings amounted to HKD 146.4 million, up from HKD 80.2 million in 2024, primarily for financing new production facilities[69] Research and Development - New R&D and production facilities in Jiangmen, Guangdong, are expected to commence trial operations in 2026, with phased commercialization thereafter[3] - Research and development expenses for the year amounted to HKD 48.7 million, representing 5.2% of total revenue, an increase from 3.8% in 2024[58] - The company plans to continue investing in R&D and strategic opportunities, focusing on expanding production capacity and developing new products[51] Corporate Governance and Compliance - The company emphasizes high standards of corporate governance to enhance accountability and transparency, aligning with stakeholder expectations and regulatory requirements[83] - The audit committee has reviewed the consolidated financial statements for the year ending December 31, 2025, ensuring compliance with relevant accounting standards[86] - The company has adopted the standard code of conduct for securities trading by directors, confirming compliance throughout the year[84] - The company will ensure compliance with corporate governance codes while seeking suitable candidates for the board[83] Future Outlook and Market Performance - The company maintains a cautious outlook for the future, aiming to enhance operational efficiency and explore strategic opportunities in the Asian market[52] - Sales in Spain increased by 43.6%, accounting for 39.5% of total revenue, while the U.S. market contributed 32.0% of total revenue[53] - The company is committed to sustainable development through environmental and social measures, with a detailed report to be included in the 2025 annual report[85]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示概不對因本公佈全部或任何 部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 Vincent Medical Holdings Limited 永勝醫療控股有限公司 （於開曼群島註冊成立之有限公司） （股份代號：1612） 董事會會議日期 香港，2026年3月10日 於本公告日期，董事會成員包括執行董事蔡文成先生、蔡章泰先生、許明輝先生 及符國富先生；非執行董事梁明珠博士；及獨立非執行董事莫國章先生、區裕釗 先生及容啟亮教授。 永勝醫療控股有限公司（「本公司」）董事（「董事」）會（「董事會」）謹此宣佈，本公司 將於2026年3月25日（星期三）舉行董事會會議，藉以（其中包括）考慮及批准本公 司及其附屬公司截至2025年12月31日止年度之末期業績、刊發有關末期業績以及 派付末期股息（如有）。 代表董事會 永勝醫療控股有限公司 主席兼執行董事 蔡文成 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年2月28日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 永勝醫療控股有限公司 呈交日期: 2026年3月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01612 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | HKD | | 0.01 HKD | | 100,000,000 | | 增加 / 減少 (-) | | | 0 | | | HKD | | 0 | | 本月底結存 | | | 10,000,000,000 | HKD | | 0.01 HKD | | 100,000,000 | 本月底法定/註冊股本總額： HKD 10 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 永勝醫療控股有限公司 呈交日期: 2026年2月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01612 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | HKD | | 0.01 | HKD | | 100,000,000 | | 增加 / 減少 (-) | | | 0 | | | | HKD | | 0 | | 本月底結存 | | | 10,000,000,000 | HKD | | 0.01 | HKD | | 100,000,000 | 本月 ...

Core Viewpoint - Yongsheng Medical (01612) has experienced a stock price increase of over 9% following the announcement of a positive earnings forecast, with shares trading at HKD 0.94 and a transaction volume of HKD 5.3888 million [1] Group 1: Earnings Forecast - The company anticipates an unaudited consolidated profit attributable to shareholders of no less than HKD 100 million for the fiscal year ending December 31, 2025 [1] - For the fiscal year ending December 31, 2024, the audited profit attributable to shareholders is expected to be approximately HKD 69.2 million [1] Group 2: Reasons for Growth - The board attributes the significant increase in revenue to strengthened relationships with a major customer in the imaging disposable products segment and the expansion of business scale [1] - The company has achieved better economies of scale by enhancing capacity utilization and operational efficiency, leading to improved gross profit margins [1]

Core Viewpoint - Yongsheng Medical (01612) has issued a positive earnings forecast, leading to a stock price increase of over 9%, with the current price at 0.93 HKD and a trading volume of 5.704 million HKD [6]. Financial Performance - The company anticipates an unaudited consolidated profit attributable to shareholders of no less than 100 million HKD for the fiscal year ending December 31, 2025, compared to an audited profit of approximately 69.2 million HKD for the fiscal year ending December 31, 2024 [6][1]. - The expected profit increase is attributed to strengthened relationships with a major customer in the imaging disposable products segment and business expansion, which significantly boosts revenue [6][1]. Operational Efficiency - The company has achieved better economies of scale by enhancing capacity utilization and operational efficiency, leading to an improved gross profit margin [6][1].

Core Viewpoint - Yongsheng Medical (01612) experienced a stock price increase of over 9% following a profit alert, with shares trading at HKD 0.94 and a transaction volume of HKD 5.3888 million [1] Financial Performance - The company anticipates an unaudited consolidated profit attributable to shareholders of no less than HKD 100 million for the fiscal year ending December 31, 2025 [1] - For the fiscal year ending December 31, 2024, the audited profit attributable to shareholders is expected to be approximately HKD 69.2 million [1] Business Drivers - The significant increase in revenue is attributed to strengthened relationships with a major customer in the imaging disposable products segment and the expansion of business scale [1] - The company has achieved better economies of scale by enhancing capacity utilization and operational efficiency, leading to improved gross margins [1]

Core Viewpoint - Yongsheng Medical (01612.HK) expects to record an unaudited consolidated profit attributable to owners of no less than HKD 100 million for the year ending December 31, 2025, compared to an audited profit of approximately HKD 69.2 million for the year ending December 31, 2024 [1] Group 1 - The anticipated profit increase is primarily attributed to strengthened relationships with a major customer in the imaging disposable products segment and the expansion of business scale, leading to a significant rise in revenue [1] - The company has achieved better economies of scale by enhancing capacity utilization and operational efficiency, which in turn has improved gross profit margins [1]